Crohn-betegség: vizsgálatok itt: Olaszország
52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Bari, Bologna, Florence, Messina, Milan, Monserrato, Naples, Negrar, Palermo, Pontedera, Rome, Rozzano, Turin
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Bari, Bologna, Florence, Messina, Milan, Monserrato, Naples, Negrar, Palermo, Pontedera, Rome, Rozzano, Turin
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Bologna, Brescia, Catanzaro, Milan, Negrar, Padova, Pisa, Rome, Rozzano, San Donato Milanese, San Giovanni Rotondo, Turin
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 2. fázisTaking peopleA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Where
- Florence, Milan, Monza, Negrar, Rome, Rozzano
- Életkor
- 18 év to 80 év
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00 - 2. fázisTaking peopleA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Where
- Florence, Milan, Monza, Negrar, Roma, Rozzano
- Életkor
- 18 év to 80 év
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483099 - 3. fázisTaking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Alexandria, Bergamo, Bologna, Florence, Milan, Rome
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Bergamo, Bologna, Rome, San Giovanni Rotondo, Trieste
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Cagliari, Castellana Grotte, Milan, Monza, Negrar, Rome, Rozzano, Turin
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - No phaseTaking peopleA Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
- Where
- Castellana Grotte, Feltre, Florence, Milan, Negrar, Padova, Roma, Rome, San Giovanni Rotondo
- Életkor
- 18 év and over
- People
- 378 worldwide
- Run by
- Alimentiv Inc.
See details and how to joinNCT07363044 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Bologna, Bolzano, Genova, Milan, Roma, Rozzano, Torino
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Milan, Negrar, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Bologna, Milan, Palermo, Rome, Rozzano
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 4. fázisTaking peopleA study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
- Where
- Milan, Rho, Rome
- People
- 16 worldwide
- Run by
- Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Bologna, Brescia, Matera, Milan, Negrar, Rome, San Donato Milanese
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Legnano, Milan, Rome, Rozzano, San Donato Milanese, Turin
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Rozzano, Turin
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Genoa, Messina, Naples, Rome
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - No phaseTaking peopleMicroencapsulated Sodium Propionate in IBD Microbiota Modulation
- Where
- Padova
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- University of Padova
See details and how to joinNCT07883044 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Bari, Catanzaro, Florence, Milan, Monserrato, Monza, Naples, Padova, Pavia, Rho, Rome, Rozzano, San Giovanni Rotondo, Turin
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - No phaseTaking peopleEstimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)
- Where
- San Donato Milanese
- Életkor
- 16 év and over
- People
- 600
- Run by
- IRCCS Policlinico S. Donato
See details and how to joinNCT07095634 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Legnano, Messina, Milan, Negrar, Padova, Rome, Rozzano, Turin
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00 - 3. fázisTaking peopleA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Messina, Milan, Pescara, Rome
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00 - 3. fázisTaking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- Bergamo, Bologna, Florence, Milan, Roma, Rome
- Életkor
- 2 év to 19 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - 3. fázisTaking peopleA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Where
- Alexandria, Bergamo, Bologna, Florence, Milan, Rome
- Életkor
- 2 év to 17 év
- People
- 90 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00